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Abstract
Rapidly progressive Alzheimer’s disease (rpAD) is a particularly aggressive form of Alzheimer’s 
disease, with a median survival time of 7–10 months after diagnosis. Why these patients have such 
a rapid progression of Alzheimer’s disease is currently unknown. To further understand 
pathological differences between rpAD and typical sporadic Alzheimer’s disease (sAD) we used 
localized proteomics to analyze the protein differences in amyloid plaques in rpAD and sAD. 
Label-free quantitative LC-MS/MS was performed on amyloid plaques microdissected from rpAD 
and sAD patients (n=22 for each patient group) and protein expression differences were 
quantified. On average, 913±30 (mean±SEM) proteins were quantified in plaques from each 
patient and 279 of these proteins were consistently found in plaques from every patient. We found 
significant differences in protein composition between rpAD and sAD plaques. We found that 
rpAD plaques contained significantly higher levels of neuronal proteins (p=0.0017) and 
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significantly lower levels of astrocyte proteins (p=1.08x10−6). Unexpectedly, cumulative protein 
differences in rpAD plaques did not suggest accelerated typical sAD. Plaques from patients with 
rpAD were particularly abundant in synaptic proteins, especially those involved in synaptic vesicle 
release, highlighting the potential importance of synaptic dysfunction in the accelerated 
development of plaque pathology in rpAD. Combined, our data provides new direct evidence that 
amyloid plaques do not all have the same protein composition and that the proteomic differences 
in plaques could provide important insight into the factors that contribute to plaque development. 
The cumulative protein differences in rpAD plaques suggest rpAD may be a novel subtype of 
Alzheimer’s disease.
Introduction
The rate of progression of sporadic AD (sAD) varies widely between patients. Rapidly 
progressive AD (rpAD) occurs in a minor subset of patients; defined as having a disease 
survival of <3yrs (median survival time of 7–10 months) after diagnosis, that often leads to a 
clinical misdiagnosis of Creutzfeldt-Jakob disease (CJD), with AD only confirmed at 
autopsy[18, 68]. The accelerated progression of rpAD occurs in the absence of an autosomal 
dominant pattern of dementia or any pathogenic mutations in the APP, PSEN1, PSEN2 or 
PRNP genes. Research examining rpAD is limited; however the amyloid plaque and 
neurofibrillary tangle morphology and distribution, as well as CSF levels of total tau, 
phosphorylated tau, Aβ40 and Aβ42 are similar to sAD[18, 68]. Distinctions with sAD 
include a younger average age at onset, a low frequency of the APOE e4 allele, a higher 
proportion of patients having 14-3-3 in the CSF, and increased serum levels of specific pro-
inflammatory cytokines (IL-6, IL-13, TNFα, G-CSF)[18, 68, 75]. Depending on how rpAD 
is defined, its frequency is estimated at ~10% of all AD cases[17]. At autopsy rpAD patients 
have similar neuropathology to sAD, although there is a higher prevalence of a low degree of 
pathology using standard NIA-Alzheimer’s Association guidelines[18, 51]. Additionally, it 
was recently shown that Aβ42 oligomers in rpAD have distinct properties, which promote 
the faster spread of Aβ42 pathology and may represent a separate “strain” of a prion-like Aβ 
conformation [17, 18].
Amyloid plaques primarily consist of Aβ, but they also contain a diverse range of amyloid 
binding proteins (e.g. apolipoprotein E [apoE], clusterin, ubiquitin, α-synuclein, etc.) and 
proteins found in astrocytes, microglia and dystrophic neurites that surround and infiltrate 
plaques. Amyloid binding proteins can significantly modulate the aggregation state of Aβ, 
and plaque-associated glia may have an important role in limiting or accelerating the 
pathological spread of amyloid[62]. For example apoE was first identified as an amyloid 
associated protein[84], prior to the discovery that inheritance apoE4 allele is the most 
significant genetic risk factor for sAD[62, 88]. ApoE modulates the aggregation and 
clearance of Aβ in an isoform specific manner[62, 88]. Hence, the relative amount of these 
non-amyloid plaque components could have an important mechanistic role in the 
development and spread of amyloid pathology in AD.
Traditionally, plaque associated proteins have been determined using targeted 
immunohistochemistry. However, the use of an alternative approach to identify plaque 
Drummond et al. Page 2
Acta Neuropathol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
associated proteins, such as mass spectrometry, has many potential benefits over 
immunohistochemistry; proteomic studies are unbiased and therefore can identify novel 
proteins involved in AD pathogenesis and drug targets, protein abundance can be accurately 
quantified, it uses microscopic amounts of tissue, it is not limited by the availability and 
specificity of antibodies, and it allows the quantification of hundreds of proteins at once 
meaning that the involvement of pathways/families of proteins can examined at the same 
time. The vast majority of human tissue samples available for research are archived 
formalin-fixed and paraffin embedded (FFPE) tissue blocks collected at autopsy. Many 
previous studies have confirmed that mass spectrometry can be successfully performed using 
FFPE tissue and that similar proteomics data can be generated from FFPE and frozen tissue 
samples[10, 23, 27, 81, 93]. We recently developed a novel method combining laser capture 
microdissection and LC-MS/MS that allows localized proteomics using microscopic 
amounts of microdissected FFPE tissue[23]. Therefore, given that amyloid plaques rapidly 
develop and accumulate in rpAD, it was the aim of this study to use localized proteomics to 
compare the proteome of plaques in rpAD and typical, sporadic AD (sAD) with the goal of 
identifying proteins that are mechanistically involved in the rapid development and 
progression of amyloid pathology. We found that the protein composition of rpAD and sAD 
plaques was significantly different. rpAD plaques contain more neuronal proteins 
(particularly synaptic proteins and those involved in actin cytoskeleton signaling) and sAD 
plaques contain more astrocyte proteins. Our data provides further evidence that rpAD may 
be a separate subtype of AD.
Methods
Ethics statement
All procedures were performed under protocols approved by the Institutional Review Board 
at Case Western Reserve University and University Hospitals Case Medical Center in 
Cleveland, OH and New York University Alzheimer Disease Center, NY. In all cases, written 
informed consent for research was obtained from the patient or legal guardian, and the 
material used had appropriate ethical approval for use in this project. All patients’ data and 
samples were coded and handled according to NIH guidelines to protect patients’ identities.
Patients and clinical evaluations
The rpAD cohort was randomly selected from a group of 276 patients with a 
neuropathological diagnosis of AD who were referred to the National Prion Disease 
Pathology Surveillance Center with a clinical diagnosis of possible CJD[18]. The inclusion 
and exclusion criteria are detailed in Cohen et al.[18], with the neuropathological features of 
the rpAD cases having no significant differences with sAD. The rpAD cases had no 
evidence of increased α-synuclein or TDP43 pathology (compared to sAD) or any evidence 
of prion disease[18]. The sporadic AD cohort was randomly included from donated brain 
tissue collected at the Department of Pathology at Case Western Reserve University and at 
the New York University Alzheimer’s Disease Clinical Center (NYU ADC). Individual 
patient information (sex, age, disease duration, ABC neuropathological score [51], post-
mortem interval time [PMI] and average size of microdissected plaques) is included in Table 
1 (except for a few cases were PMI was not recorded). For the sAD cases, who were 
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followed longitudinally at either the NYU ADC or at Case Western University, disease 
duration was defined as the time between a designation of a CDR diagnosis of 1 and/or a 
GDS of 4 [53, 64], until death. For the rpAD cases this interval was defined as the time 
between the patient initially presenting to medical attention with cognitive symptoms, and 
death. Most of the rpAD cases were not evaluated at specialist Dementia Centers, but were 
referred to the Prion Disease Surveillance Center at autopsy with a possible clinical 
diagnosis of CJD. 22 cases of rpAD and 22 cases of sAD were included in this study. As this 
is the first time that a quantitative proteomics study analyzing amyloid plaque protein 
composition has been reported, a sample size calculation could not be performed. This 
sample size was selected based on the degree of inter-patient variance observed in pilot 
studies.
Laser Capture Microdissection
Formalin-fixed, paraffin embedded (FFPE) tissue blocks containing the hippocampus that 
were collected and processed as part of routine autopsy procedures were used in this study, 
which were matched in the rpAD and sAD cases. A subset of these tissue blocks were 
treated with 98% formic acid prior to paraffin embedding because of the presence of 
suspected prion disease. Formic acid treated tissue blocks were immersed in 98% formic 
acid for 1 hour at room temperature, rinsed 3 times with 10% formalin and allowed to post-
fix with 10% formalin for an additional 48 hours prior to standard paraffin embedding. 
Immunostaining for amyloid plaques and laser capture microdissection (LCM) was 
performed using the method detailed in Drummond et al.[23]. Briefly, 8μm sections of FFPE 
tissue blocks were collected onto LCM-compatible slides and amyloid plaques were 
visualized using fluorescent immunohistochemistry using a combination of the pan-Aβ 
antibodies 4G8 (1:4000; BioLegend; Catalog #800709) and 6E10 (1:4000; BioLegend; 
Catalog #803001). LCM was performed using a LMD 6500 microscope (Leica). 2mm2 total 
area of fluorescently-labeled plaques was manually selected, microdissected using LCM and 
collected into double distilled water. Samples were stored at −80°C until sample processing 
for LC-MS.
Effect of formic acid treatment on LC-MS/MS
An initial study examining the effect of formic acid treatment of tissue blocks on 
downstream proteomics was completed. For this study 3 cases of sAD were included. At 
autopsy two consecutive hippocampal tissue blocks were collected; one was treated with 
formic acid prior to paraffin embedding using the method described above and the other was 
paraffin embedded only. 2mm2 of plaques were microdissected from all 6 samples using the 
method described above.
LC-MS/MS
Samples were processed for label-free quantitative LC-MS/MS analysis using the formic 
acid extraction protocol detailed in Drummond et al.[23]. Briefly, plaques were 
deparaffinized by heating at 95°C for one hour followed by 65°C for 2 hours and incubated 
in 70% LC-MS grade formic acid overnight at room temperature. Samples were sonicated 
three times for three minutes with a few seconds of votexing in between. Samples were dried 
using a SpeedVac concentrator, resuspended in 100mM ammonium bicarbonate and then 
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reduced with Dithiothreitol (20mM) and alkylated with iodoacetamide (50mM). Protein 
samples were digested with 200ng of sequencing grade modified trypsin (Promega) 
overnight at room temperature with gentle agitation. Samples were acidified with 0.2% TFA 
and peptides were desalted using Poros beads. Briefly, a slurry of R2 20μm Poros beads 
(Life Technologies Corporation) was added to each sample. Samples were incubated with 
agitation at 4°C for 4 hours. The beads were loaded onto equilibrated C18 ziptips 
(Millipore) using a microcentrifuge for 30sec at 6000RPM. Poros beads were rinsed three 
times with 0.1% TFA followed by microcentrifugation. Extracted poros beads were further 
washed with 0.5% acetic acid. Peptides were eluted off the beads by addition of 40% 
acetonitrile in 0.5% acetic acid followed by the addition of 80% acetonitrile in 0.5% acetic 
acid. The organic solvent was removed using a SpeedVac concentrator and the samples were 
reconstituted in 0.5% acetic acid.
An aliquot of each sample was loaded onto the EASY spray 50cm C18 analytical column 
with <2μm bead size using the auto sampler of an EASY-nLC 1000 HPLC (ThermoFisher) 
in solvent A (2% acetonitrile, 0.5% acetic acid). The peptides were gradient eluted directly 
into a Q Exactive (Thermo Scientific) mass spectrometer using a two hour gradient from 2% 
to 30% solvent B (90% acetonitrile, 0.5% acetic acid), followed by 10 minutes from 30% to 
40% solvent B and 10 minutes from 40% to 100% solvent B. The Q Exactive mass 
spectrometer acquired high resolution full MS spectra with a resolution of 70,000, AGC 
target of 1e6, with a maximum ion time of 120 ms, and scan range of 400 to 1500 m/z. 
Following each full MS twenty data-dependent high resolution HCD MS/MS spectra were 
acquired using the resolution of 17,500, AGC target of 5e4, maximum ion time of 120 ms, 
one microscan, 2 m/z isolation window, fixed first mass of 150 m/z, Normalized Collision 
Energy (NCE) of 27 and dynamic exclusion of 30 seconds.
Samples were processed and analyzed using LC-MS in three different batches. Batch #1 
consisted of n=3 sAD cases that were used for the formic acid block treatment test. Batch #2 
consisted of n=10 rpAD and n=8 sAD cases. Batch #3 consisted of n=12 rpAD cases and 
n=11 sAD cases.
Proteomics Computational Analysis
Protein quantitation was performed using MaxQuant software suite (Version 1.5.2.8)[19]. 
The MS/MS spectra were searched against the Uniprot Human reference proteome database 
(downloaded 2-25-16) using Andromeda within MaxQuant including Carbamidomethylation 
of Cysteine as a fixed modification and oxidation of methionine, acetylation of protein 
NTerm, formylation of lysine, phosphorylation of serine, threonine and tyrosine, 
deamidation of glutamine and asparagine as variable modifications. Both unique and razor 
peptides were considered for quantitation. Unique peptides are present only in a single 
protein and razor peptides are unique to a given protein group. The mass tolerance was set to 
10ppm and 20ppm for MS1 and MS/MS searches respectively. False discovery rate (FDR) 
filtration was done first on peptide level and then on protein level. Both filtrations were done 
at 1% FDR using a standard target-decoy database approach. The MaxQuant grouped two 
homologous proteins or isoforms with different Uniprot identifiers, when they could not be 
distinguished based on the identified peptides. The identification of a protein group doesn’t 
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imply that all proteins in the group are present, rather that at least one protein in the group is 
present[70].
Proteomics Data Analysis
The bioinformatics analysis was performed using open source software Perseus (Version 
1.5.2.6). All the proteins identified with less than two unique+razor peptides were excluded 
from analysis. The results were further filtered to remove common contaminant proteins and 
reverse identifications. The intensity values were log2 transformed and missing values were 
imputed based on normal distribution. A two-sided Welch’s t-test and Benjamini-Hochberg 
FDR was performed. All expression levels, ratios and p-values were reported, but only 
protein groups having an estimated FDR less than the cut-off level of 5% were considered 
significantly up- or down-regulated in rpAD vs sAD. Principal Component Analysis (PCA) 
was applied to the entire expression matrix using the R statistical computing system.
Ingenuity Pathway Analysis (IPA)
Pathway analysis was completed using IPA (Qiagen). FDR adjusted Welch’s t-test p-values 
(q-values) and rpAD/sAD protein expression ratios for differently expressed proteins were 
uploaded into IPA. Significantly altered proteins were mapped to canonical pathways and 
disease/functional networks, which were determined to be statistically enriched using a 
right-tailed Fisher’s Exact Test in comparison to the background dataset of all proteins 
identified in plaques, with the threshold for significance set to p<0.05. IPA was also used to 
identify upstream regulator proteins, which were determined based on prior knowledge of 
expected effects between regulator and target proteins/genes stored in the Ingenuity 
Knowledge Base. This analysis determined whether known target proteins in the uploaded 
list of significantly altered proteins in rpAD plaques were enriched for a particular upstream 
regulator (statistically determined using Fisher’s Exact Test and threshold for significance 
set to p<0.01) and compared the direction of change of expression of each of the these target 
proteins to determine an activation z-score, which was a measure of probability of activation 
or inactivation of a particular upstream regulator (with threshold for activation set to z-
score>2 and inactivation set to z-score<−2)[41].
STRING protein interaction analysis
Genes (that encoded for proteins identified in the proteomic analysis) were uploaded into the 
online STRING database (Version 10.0), which identifies protein-protein interactions and 
functional enrichment in comparison to the whole human genome in the following 
categories; biological process, molecular function, cellular component, KEGG pathways, 
PFAM protein domains and INTERPRO protein domains and features[79]. Two lists of 
genes were analyzed using STRING; genes encoding for all proteins present in plaques 
(found in Supplementary Table 1) and genes encoding for all proteins with significantly 
altered expression in rpAD plaques (found in Supplementary Table 3).
Proteomic comparison with Alzheimer’s disease database
A compilation of proteins with published association with AD was generated. This database 
combined the results from studies that identified proteins in neurofibrillary tangles[50, 66, 
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82], proteins enriched in plaques[32, 43], proteins that had significantly altered expression in 
various regions and/or fractions of AD brains in comparison to control brains and proteins 
that contained the keyword “Alzheimer” in the Uniprot human database[1, 2, 4, 11, 13, 14, 
22, 31–33, 36, 37, 45, 54, 55, 77, 78, 89, 90, 96]. Protein groups identified in rpAD and sAD 
plaques were screened against this database to determine how many of the proteins 
identified in this study have been previously associated with AD pathology. Protein groups 
were annotated as up- or down-regulated in AD if they were previously reported as up- or 
down-regulated at least once and where no inconsistent reports were found. The proportion 
of up- and down-regulated proteins was compared in proteins that were found to be 
significantly increased or decreased in rpAD plaques using proteomics analysis. The 
resulting contingency table (Figure 3f) was analyzed using Fisher’s exact test.
Cell-type specificity
Genes (that encoded for the proteins identified using proteomics) were assigned cell-type 
specificity based on data published in Zhang et al.[94]. For each gene an average expression 
level was calculated per one of five possible cell types: neurons, astrocytes, microglia, 
oligodendrocytes or endothelial cells, where only expression in mature, non-diseased human 
cell types was considered. Only gene expression data from anti-GalC hybridoma supernatant 
harvested oligodendrocytes was used to determine oligodendrocyte specificity for our study, 
as this resulted in the purification of more mature oligodendrocytes in comparison to the 
oligodendrocyte precursor cells purified using anti-O4 hybridoma supernatant. Each gene’s 
mean expression level per cell type was row-normalized – if more than 66% of the 
normalized expression was attributable to any single cell-types, the gene was considered 
specific to that cell type. A two-tailed Fisher’s exact test was used to find significant 
associations between the resulting gene lists and a dichotomization of the protein-groups 
based on the sign of their log2-ratios (i.e. based on whether their rpAD/sAD ratios were 
positive or negative). Two cell-types were significantly associated with the up/down-
regulated dichotomy even after Bonferroni correction.
Fluorescent immunohistochemistry
8μm thick FFPE tissue sections consecutive from those used for LCM were stained using 
fluorescent immunohistochemistry. Immunostaining was performed on one section 
containing the hippocampus and adjacent cortex per case for each staining combination. 
Sections were deparaffinized and rehydrated through a series of xylene and ethanol washes. 
Antigen retrieval was performed by treatment with 88% formic acid for 7min, followed by 
boiling in citrate buffer (10mM sodium citrate, 0.05% Tween-20; pH6). Sections were 
blocked with 10% normal goat serum, incubated overnight at 4°C with a combination of 
anti-Aβ antibodies 4G8 (1:4000; BioLegend; Catalog #800709) and 6E10 (1:4000; 
BioLegend; Catalog #803001), and with either anti-GFAP (1:1000; Dako; Z0334) to label 
astrocytes, anti-SMI312 (1:500; BioLegend; Catalog # 837901) to label dystrophic neurites 
or anti-Secernin-1 (1:50; LSBio; Catalog # LS-C162903). All primary antibodies were 
diluted in 4% normal goat serum in PBS. Sections were then incubated for 2 hours at room 
temperature with appropriate fluorescent secondary antibodies (all diluted 1:500, from 
Jackson ImmunoResearch). Sections were counter stained with Hoechst 33342 (Sigma) and 
coverslipped (PermaFluor, Thermo Fisher Scientific).
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Quantification of amyloid plaque burden, and plaque-associated dystrophic neurites and 
astrocytes
Fluorescent imaging of the whole section was performed at 20x magnification using a 
NanoZoomer HT2 (Hamamatsu) whole slide scanner using the same settings for all slides. 
Four images containing the cortex were collected at 4x magnification per case for 
quantification. Quantification was performed using ImageJ. Amyloid burden was determined 
by thresholding the Aβ image to identify all pixels with positive Aβ labelling and the 
percentage Aβ burden in the cortex was calculated as the percentage of Aβ positive pixels in 
the total cortex area. Quantification of plaque-associated astrocytes and dystrophic neurites 
was performed by thresholding the Aβ cortex images to identify pixels with positive Aβ 
labelling followed by the “Analyze Particles” command to remove clusters of thresholded 
pixels with a combined area of less than 100 pixels to ensure that only plaque associated Aβ 
staining remained. As we were interested to see the amount of plaque associated dystrophic 
neurites and astrocytes, we then applied the “Enlarge” function to expand the area associated 
with each plaque to contain the Aβ-positive plaque core and the surrounding 50μm of 
plaque-associated tissue, consistent with published methodology[72]. A mask of the area 
selected in this plaque image was then applied to the corresponding GFAP or SMI312 
stained image and the percentage burden (% of pixels with positive staining for GFAP or 
SMI312) and the average GFAP or SMI312 staining intensity was quantified in the plaque-
associated area. Statistical comparison of burden and intensity between rpAD and sAD was 
performed using an unpaired t-test.
Representative images for figures were collected using a Zeiss LSM700 Confocal 
Microscope. Individual images were collected every 1μm through the width of the 8μm 
sections at 20x magnification and presented images show the maximum projection image. 
All images of a particular stain were collected using the same confocal settings.
Results
Amyloid plaque proteome
The amyloid plaque proteome was compared in 22 cases of rpAD and 22 cases of sAD that 
were matched for sex and tissue archival time (Table 2). The cohort of rpAD patients was 
randomly selected from the larger cohort reported in Cohen et al. [18]. Consistent with this 
previous study, the cohort of rpAD patients used in the current study had a >10 fold shorter 
disease duration (9.2±1.3 months) than patients with typical sAD (122±8.0 months), and 
rpAD patients were younger than sAD patients (Table 2). The distribution and morphology 
of amyloid plaques was similar between these rpAD and sAD cases[18]. Diffuse and neuritic 
plaques were present in both subtypes. Therefore, as both plaque subtypes proliferate rapidly 
in rpAD and this was the first time that such a large scale proteomic study has been done 
examining the amyloid plaque proteome, we microdissected and pooled both diffuse and 
neuritic plaques observed in the hippocampus and adjacent entorhinal cortex in each case. 
On average, each sample consisted of approximately 740 plaques and there was no 
difference in the number or size of plaques collected between rpAD and sAD cases (Table 
2). On average, 913±30 (mean±SEM) proteins were quantified in plaques from each case 
and the number of proteins quantified in rpAD and sAD plaques were similar. As expected, 
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there was some inter-patient variation in the specific proteins present in plaques (particularly 
in proteins with low abundance), resulting in quantification of 1934 proteins across all cases 
(Supplementary Table 1). Of these proteins, 279 were consistently detected in plaques from 
every case, regardless of whether rpAD or sAD (Table 3; Supplementary Table 2). These 
consistently detected, abundant plaque proteins included proteins previously confirmed to be 
present in amyloid plaques such as Aβ, apoE, ubiquitin, tau, GFAP and clusterin, therefore 
validating mass spectrometry proteomics as an alternative approach to 
immunohistochemistry for determining the composition of amyloid plaques. In sum, 86% 
(240/279 proteins) of the consistently detected, abundant plaque proteins had been 
associated with AD in previous proteomic studies (Supplementary Table 2). Our use of an 
unbiased mass spectrometry approach not only allowed sensitive and accurate identification 
of amyloid plaque proteins, but also permitted the detection of many novel proteins present 
in amyloid plaques. The most important example being the numerous novel plaque proteins 
that were consistently detected in all cases examined (Supplementary Table 2), suggesting 
that these proteins may have an important mechanistic role in plaque development. One 
example of a novel plaque protein identified using LC-MS was secernin-1. Secernin-1 was 
selected for further validation because of its consistently high expression in plaques in every 
patient, and the availability of a commercial antibody generated using an immunogen that 
directly corresponded with a peptide identified using LC-MS. Fluorescent 
immunohistochemistry was used to validate secrenin-1 expression in plaques in sAD and 
rpAD in comparison to basal expression in age-matched control tissue. A similarly high 
expression of secernin-1 was observed in plaques in rpAD and sAD, consistent with what 
would be expected based on LC-MS results. Particularly strong immunolabelling for 
secernin-1 appeared to be in plaque-associated dystrophic neurites, in addition to some 
weaker diffuse staining throughout plaques (Figure 1). Weak cytoplasmic staining appeared 
to be present in neurons in age-matched control tissue (95 years, Braak stage I/VI; Figure 
1f).
Significantly different proteome of rpAD plaques
The main goal of this study was to determine whether the plaque proteome was significantly 
different in rpAD and sAD. Principal component analysis (PC2) showed an almost complete 
separation of sAD and rpAD cases, providing convincing evidence that rpAD plaques 
contained a significantly different protein composition than sAD plaques (Figure 2a; 
p=2.08x10−8). Separation of cases by PC1 was due to differences between batches of 
samples. While it is regrettable that there were apparent technical differences in either 
sample preparation or LC-MS analysis between batches of samples, this result actually 
increases our confidence in the proteomic differences between rpAD and sAD plaques, 
which were robust enough to overcome these batch differences. Quantification of individual 
proteins showed that 141 proteins had significantly different expression in rpAD and sAD 
plaques (Figure 2b; Supplementary Table 3); 85 had significantly higher expression in rpAD 
plaques (Table 4) and 56 had significantly lower expression in rpAD plaques (Table 5). 
Many of the proteins with significantly altered expression have been previously associated 
with the development and maintenance of amyloid plaques. For example, there were 
significantly lower levels of Aβ (p<0.001), gelsolin (p<0.01) and GFAP (p<0.0001) in rpAD 
plaques and significantly more α-synuclein (p<0.01), indicating that these proteins have a 
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particularly important role in the rapid development of amyloid plaques that occurs in rpAD 
(Figure 2c). This role appeared to be unique to these specific proteins as levels of other 
important plaque associated proteins (such as tau, ubiquitin and apoE) were similar in rpAD 
and sAD plaques (Supplementary Table 1). The unbiased mass spectrometry approach used 
in this study also highlighted the important role in plaque development for many novel 
proteins that have not been previously associated with amyloidosis or AD. Most interesting 
was the dramatic increase in expression of POTEE/ACTBM in rpAD plaques (Figure 2c; 
11.47 fold difference; p=1.73x10−8). We were not able to distinguish whether the increased 
protein was POTEE or ACTBM (which is encoded by the gene POTEKP, a pseudogene of 
the POTE family) based on the identified peptides. The C-terminus sequence of POTEE is 
homologous to the different actin isoforms (ACTA, ACTB, ACTBM, ACTC, ACTS etc.). In 
our results POTEE and ACTBM are grouped separately from other actin isoforms due to 
identification of the peptide “VAPEEHPILLTEAPLNPK” which is shared between POTEE 
and ACTBM but no other actin isoforms (Supplementary Figure 1). Importantly, this peptide 
is approximately 10 fold higher in rpAD than sAD plaques, thereby showing that POTEE or 
ACTBM is increased in rpAD rather than other actin isoforms. Neither POTEE nor ACTBM 
have been previously associated with AD, so the large increase in the expression of this 
protein in rpAD plaques is suggestive of a novel pathological pathway involved in the rapid 
progression of plaque pathology in rpAD.
An unavoidable variable encountered in this study was that rpAD brain tissue was treated 
with formic acid during autopsy tissue collection because clinical symptoms in these 
patients resulted in a clinical diagnosis of possible CJD, and therefore tissue blocks were 
treated with formic acid prior to paraffin embedding according to prion tissue protocol. As 
this was not standard protocol for sAD tissue, additional experiments were necessary to 
determine if formic acid treatment of brain tissue prior to LCM was compatible with LC-MS 
and to ensure that formic acid treatment did not significantly alter downstream protein 
detection. To do this, two consecutive blocks of hippocampal tissue were collected from 
three sAD cases; one treated with formic acid prior to paraffin embedding and one that was 
not. Quantitative LC-MS showed that formic acid treatment of tissue blocks did not 
significantly alter the type or abundance of proteins detected in plaques (Supplementary 
Table 4), ensuring that any protein differences observed between rpAD and sAD plaques 
were not a result of formic acid treatment of tissue blocks.
Cell type specific protein changes in rpAD plaques
We were interested to determine whether protein differences in rpAD plaques were 
predominantly associated with a specific cell type. Therefore, we compared our proteomic 
data with the RNA sequencing dataset recently published by Zhang et al.[94], who examined 
RNA expression in neurons, astrocytes, microglia, oligodendrocytes and endothelial cells 
isolated directly from healthy adult human temporal cortex collected during surgery, 
therefore allowing identification of genes that are specific to each particular cell type. We 
found that rpAD plaques contained significantly higher levels of neuronal proteins 
(p=0.0017) and significantly lower levels of astrocyte proteins (p=1.08x10−6). The number 
of microglial, oligodendrocyte and endothelial cell-type specific proteins were low in 
plaques and there was no significant difference in the amount of these proteins between 
Drummond et al. Page 10
Acta Neuropathol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
rpAD and sAD plaques (Figure 3). Fluorescent immunohistochemistry was performed to 
determine if the increased amount of neuronal proteins and the decreased amount of 
astrocyte proteins in rpAD plaques were due to increased numbers of plaque-associated 
dystrophic neurites and decreased numbers of plaque-associated astrocytes respectively. 
Indeed, plaque-associated astrocytosis was found to be significantly lower in rpAD than 
sAD (Figure 4a, b, g), confirming our proteomic results and suggesting that the cumulative 
decrease in astrocyte proteins in rpAD plaques was a result of decreased number of plaque 
associated astrocytes. In contrast, the number of plaque associated dystrophic neurites was 
similar in rpAD and sAD (Figure 4d, e, h), suggesting that the increased presence of 
neuronal proteins in rpAD plaques was not due to an increased amount of dystrophic 
neurites within plaques.
Network and pathway analyses of protein differences in rpAD plaques
The large number of protein differences between rpAD and sAD plaques suggested that 
networks of proteins, rather than individual proteins, were mechanistically involved in the 
rapid development of rpAD plaques. First, the significantly altered proteins in rpAD plaques 
were compared to our database of AD associated proteins identified in previous proteomic 
studies[1, 2, 4, 11, 13, 14, 22, 31–33, 36, 37, 43, 45, 50, 54, 55, 66, 77, 78, 82, 89, 90, 96]. 
In this database we annotated proteins as up-regulated in AD, down-regulated in AD and 
proteins that are enriched in plaques or tangles (Supplementary Table 1). We then used this 
database to apply these annotations to the proteomic data generated in this study (column 
ALZdirection in Supplementary Tables 1 and 3). Interestingly, we found a significant 
association between expression change in the literature and expression change across rpAD 
and sAD (p=2.67x10−11, Figure 3f). Specifically, it was found that protein groups with 
significantly higher expression in sAD plaques were predominantly found in previous 
studies to be up-regulated in AD, whereas proteins that had higher expression in rpAD 
plaques were found to have lower expression in AD. Ingenuity Pathway Analysis (IPA) also 
supported these results. As expected, the cumulative significant protein differences in rpAD 
plaques were most significantly associated with biological pathways affiliated with 
Neurological Disease (86/141 proteins involved; 76 individual pathways; p= 3.70x10−6 – 
4.70x10−2). Specifically, cumulative protein changes in rpAD plaques were most indicative 
of increased degeneration of the forebrain (p=3.0x10−6), dystrophy of neurites 
(p=2.90x10−5) and engulfment of cells (p=2.71x10−5). The cumulative directional changes 
of significantly altered proteins were also indicative of significantly increased amyloidosis 
(activation z-score = 2.279). All of these findings are consistent with the rapid pathological 
changes known to occur in rpAD. Based on published data IPA is also able to determine the 
likelihood of whether certain upstream regulators are activated or inhibited. Contrary to 
traditional pathological mechanisms that occur in typical sAD, the cumulative protein 
directional changes (i.e. increased or decreased expression) in rpAD plaques were 
significantly indicative of inhibition of APP/Aβ (37/141 significantly altered proteins 
regulated by APP; p=1.07x10−5; activation z-score = −2.933). Together, these results suggest 
that different pathological mechanisms beyond those mediated by APP/Aβ likely underlie 
the rapid spread of plaque pathology in rpAD. Other upstream regulators that were predicted 
to be inhibited in rpAD included the tumor suppressor protein p53 (regulates 27/141 of 
significantly altered proteins; activation z-score −3.434), mTORC2 component rictor 
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(regulated 15/141 of significantly altered proteins; activation z-score −2.840) and 
inflammatory cytokine IL-1β (regulated 15/141 of significantly altered proteins; activation 
z-score −2.207).
IPA of altered proteins in rpAD plaques showed that a number of distinct pathways were 
associated with the rapidity of the disease course. Pathways mediating actin cytoskeleton 
signaling (p=1.39x10−3), signaling by Rho family GTPases (p=4.81x10−3), virus entry via 
endocytic pathways (p=6.14x10−3) and phagosome maturation (p=6.69x10−3) were 
significantly enriched in proteins with significantly altered expression in rpAD plaques, 
suggesting that these pathways may have a mechanistic role in rpAD pathology. 
Interestingly, tau was identified as the most significant upstream regulator of significantly 
altered proteins in rpAD plaques (27/141 proteins regulated by tau upstream; p=3.99x10−6), 
suggesting that there may be an important role of tau in the accelerated plaque pathology in 
rpAD. It was also evident that proteins with significantly altered expression in rpAD plaques 
were more strongly associated with other neurological disorders ahead of AD; for example 
Huntington’s disease (31/141 proteins involved; p=6.19x10−5), Schizophrenia (22/141 
proteins involved; p=6.60x10−5) and disorders of the basal ganglia (39/141 proteins 
involved; p=7.89x10−5) in comparison to Alzheimer’s disease (20/141 proteins involved; 
p=0.0273). Finally, analysis using multiple pathway analysis tools suggested that all proteins 
present in plaques and those proteins with significantly altered expression in rpAD plaques 
were most highly enriched in vesicle proteins (STRING version 10.0; GO cellular 
component enrichment; All plaque proteins – 1021/1911 proteins [p<1.0x10−281]; 
significantly altered plaque proteins - 94/141 proteins [p=1.96x10−38]). IPA also supported 
and extended this finding, showing that the cumulative directional changes in protein 
expression in rpAD was most significantly associated with increased neurotransmission 
(activation z-score= 3.079). Together, these findings suggest that synaptic vesicle release 
may have a very important role in plaque formation and that this process is increased in 
rpAD.
Discussion
We have performed the most comprehensive analysis of amyloid plaque associated proteins 
to date, identifying numerous novel amyloid associated proteins that were present in all 
rpAD and sAD cases examined. We verified the presence of one of these novel amyloid 
associated proteins, secernin-1 (chosen based on availability of an appropriate commercial 
antibody), using standard immunohistochemical methods (Figure 1). Secernin-1 has 
previously been reported to be up-regulated in an animal model of retinitis pigmentosa[26], 
but has no prior reported association with AD. We have confirmed that amyloid plaques 
consistently contain hundreds of proteins and that this protein expression can potentially 
provide important insight into the dysfunctional mechanistic pathways that underlie AD. 
Importantly, we have shown for the first time that not all amyloid plaques contain the same 
proteins, suggesting that there may be different subtypes of plaques, which in turn could 
help to clarify the heterogeneity in AD pathogenesis between patients. We demonstrated that 
plaques from patients with rpAD contained significantly different protein expression than 
plaques from patients with sAD, suggesting that rpAD is a distinct subset of sAD. This is 
consistent with genetic data showing that rpAD has a low apoE4 allele frequency (compared 
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to sAD), which is the most important genetic risk factor for sAD, as well as biochemical 
data indicating that Aβ42 oligomers in rpAD are distinct[17, 18, 68]. The protein differences 
in rpAD plaques we document suggest that there could be different pathological mechanisms 
mediating the rapid spread of pathology in rpAD in comparison to sAD, despite the similar 
morphology and distribution of amyloid plaques and neurofibrillary tangles in rpAD and 
sAD at autopsy[18, 68]. We also verified that there were no significant differences in the 
amyloid burden in the rpAD and sAD cases in the hippocampal tissue block used for this 
proteomic study. If rpAD represents merely one side of a normal distributed duration of AD 
illness, then one might expect predominantly quantitative differences of a similar set of 
proteins in rpAD and sAD, in contrast to our finding of numerous distinct proteins in rpAD 
plaques. The principal component analysis showed an almost complete separation of sAD 
and rpAD cases with network and pathway analyses also showing significant differences, 
consistent with the hypothesis that rpAD is a distinct subset of AD.
rpAD plaques contained significantly more neuronal proteins than sAD plaques. A large 
proportion of proteins with higher expression in rpAD plaques were synaptic proteins (66% 
of proteins with increased expression in rpAD plaques), particularly key presynaptic proteins 
such as SNAP25, syntaxin binding protein 1 (munc-18), syntaxin 1A and piccolo. Many of 
the synaptic proteins with increased expression in rpAD plaques have an important 
functional role in neurotransmitter release and vesicle proteins were particularly enriched, 
hence providing new evidence to support previous studies that have proposed that synaptic 
processes have an important role in plaque development and selective vulnerability in 
AD[28, 73]. Immunohistochemistry results showed that the increased presence of synaptic 
proteins was not simply a result of increased numbers of plaque associated neurites in rpAD. 
Previous immunohistochemistry studies have confirmed that many synaptic proteins can be 
found dispersed throughout plaques[32, 65], therefore, this may be the case in rpAD plaques 
also. Aβ oligomers are known to accumulate in synapses, particularly in synapses near 
plaques[60]. Aβ oligomers are also known to be toxic to synapses[25], and the presence of 
synaptic Aβ oligomers correlates with cognitive impairment in early AD[8]. Based on these 
previous findings we propose that Aβ42 oligomers may accumulate in synapses, binding to 
key synaptic proteins, and causing synaptic dysfunction, cognitive impairment and plaque 
formation. Given the increased amount of higher order Aβ42 oligomers in rpAD[18], it is 
plausible to suggest that this process occurs to a greater extent in rpAD. This hypothesis is 
supported by a recent study that showed that Aβ oligomers bind to syntaxin 1A, which is an 
example key presynaptic protein that is up-regulated in rpAD plaques, and this binding 
prevents synaptic vesicle release and leads to synaptic impairment[87].
Another important finding from this study is that there are significantly fewer plaque 
associated astrocytes in rpAD, which was confirmed using both immunohistochemistry and 
proteomics. Previous studies suggest that plaque associated astrocytes are neuroprotective in 
AD; they are involved in clearance of oligomeric and fibrillar Aβ[58], and decreased 
numbers correlate with greater cognitive impairment[47] and accelerated plaque formation 
in transgenic mice[40]. The decreased amount of plaque associated astrocytes in rpAD 
suggests that the typical Aβ-induced astrocyte activation response was impaired in rpAD. 
This could potentially result from either dysfunctional astrocytes or from astrocytes not 
reacting to the different conformation of Aβ present in rpAD. Regardless of the underlying 
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cause, the decreased plaque-associated astrogliosis could contribute to the rapid spread of 
plaque pathology in rpAD.
The expression of POTEE/ACTBM in rpAD plaques was dramatically increased. Neither 
POTEE nor ACTBM have been previously associated with AD pathogenesis. Even the 
cellular localization and regional distribution of POTEE or ACTBM in the brain is currently 
unknown due to the lack of available appropriate antibodies. The genes for both POTEE and 
ACTBM are located in close proximity at 2q21.1. POTEE belongs to the POTE family of 
genes, which are primate specific and contain Ankyrin repeats and coiled coil domains. 
These structural features have been suggested to mediate oligomerization of proteins and 
protein-protein interactions[3]. Several POTE family members (including POTEE) contain a 
beta actin domain at the C-terminus[42], which is the region with high homology with 
ACTBM. Functionally, POTEE is known to be a tumor-associated antigen; tissue protein 
expression is low in normal circumstances, but expression is dramatically increased in a 
variety of human cancers including prostate, breast, lung, colon, ovarian and pancreatic 
cancers[5, 6, 16] and increased expression of a similar POTE family member (POTEF) 
promotes apoptosis[44]. The functional role of POTEE in the brain is currently unknown. 
Less is known about ACTBM (also known as kappa actin). Kappa actins are also associated 
with cancer; expression is increased hepatocellular carcinoma[12]. ACTBM has been 
mapped to the subcellular locations of cytoskeleton, cytosol, extracellular space, vesicles 
and exosomes (IPA). However, the functional role of ACTBM in the brain is currently 
unknown. Interestingly, pathway analysis also suggested that other proteins involved in actin 
cytoskeleton signaling were particularly abundant in rpAD plaques in comparison to sAD 
plaques. This finding could be linked to the increased amount of synaptic proteins in rpAD 
plaques as actin filaments are particularly concentrated in synapses, dendritic spines and 
growth cones[35, 48]. The cumulative protein differences in rpAD plaques indicated that 
there was an increase in proteins responsible for actin polymerization. Mechanistically an 
increase in actin polymerization could contribute to enhanced plaque formation as 
polymerized actin is capable of cross-seeding Aβ, promoting enhanced Aβ aggregation[57].
In conclusion, the differences in the rpAD plaque proteome provide new direct evidence that 
amyloid plaques do not all have the same protein composition. Whether this alternative 
pathogenesis is triggered by the higher levels of Aβ42 with distinct prion-like strain 
properties has to be addressed in future bioassay experiments[17, 18]. Our results suggest 
that proteomic differences in plaques could provide important insight into the factors that 
contribute to plaque development, which can be pursued in future targeted studies. It will be 
particularly interesting for future studies to determine the mechanistic role of presynaptic 
dysfunction and the role of POTEE/ACTBM in the development of plaques, as these could 
represent novel future drug targets specifically targeted to stop the rapid formation of 
amyloid plaques in AD. The cumulative protein differences in rpAD plaques potentially 
suggest that rpAD is a separate subtype of AD. We also identified numerous novel amyloid 
associated proteins (such as secernin-1) that could open up new therapeutic directions for 
AD.
Drummond et al. Page 14
Acta Neuropathol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Secernin-1 staining in plaques
Double fluorescent immunohistochemistry confirmed the presence of secernin-1 (green) in 
plaques (visualized using immunohistochemistry for Aβ; red). Representative images show 
secernin-1 staining in the entorhinal cortex in sAD (a), rpAD (b) and age-matched control 
(c) subjects at low magnification. Higher magnification images of the boxed regions are 
shown in d–f, which highlight the abundance of secernin-1 in plaques.
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Figure 2. Differences in the rpAD and sAD plaque proteome
(a) Principal component analysis showed a near complete separation of rpAD (blue) and 
sAD (green) plaque proteins, showing that rpAD plaques contained significantly different 
protein expression (p=2.08x10−8) (b) Volcano plot showing protein expression differences of 
all proteins identified in plaques. All proteins highlighted in red had significantly altered 
expression in rpAD plaques. Significance was determined using a two-sided Welch’s t-test 
and Benjamini-Hochberg False Discovery Rate (FDR) set to 5% (exact p-values for each 
protein group are provided in Supplementary Table 1 and 3). Proteins with higher expression 
in rpAD plaques fall to the right of the plot and proteins with lower expression fall to the left 
of the plot. Proteins of interest are identified with gene names; the 5 proteins with the most 
significant increases and decreases in rpAD plaques are highlighted, as are proteins of 
particular interest in AD pathophysiology. (c) Proteins of interest with significantly altered 
levels in rpAD plaques. Individual points show protein expression in each individual case. 
Significance was determined using an unpaired t-test with Welch’s correction. Data shows 
mean ± SEM; **** p<0.0001; *** p<0.001; ** p<0.01. All analyses were generated 
comparing 22 cases of rpAD and sAD.
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Figure 3. Cell-type specific protein expression differences in rpAD plaques
Each graph plots all proteins identified in plaques. The further the point is away from the 
dashed line at 0, the greater the difference in expression in rpAD and sAD plaques. Proteins 
with a positive log ratio have greater expression in rpAD plaques and proteins with a 
negative log ratio have a greater expression in sAD plaques. All proteins highlighted in red 
correspond to neuronal proteins (a), astrocyte proteins (b), microglial proteins (c), 
oligodendrocyte proteins (d) and endothelial cell proteins (e). The cumulative cell-type 
specific protein differences showed that there were significantly more neuronal proteins in 
rpAD plaques (p=0.0017) and significantly less astrocyte proteins in in rpAD plaques 
(p=1.08x10−6), and no differences in the amount of microglial, oligodendrocyte or 
endothelial cell proteins between rpAD and sAD plaques. Significance was determined 
using a two-tailed Fisher’s exact test comparing cumulative cell-type specific protein 
expression between rpAD (n=22) and sAD (n=22). (f) Shows a contingency table after 
comparison with the AD database. Proteins in the AD database were annotated as either up- 
or down-regulated in AD according to previous proteomics studies. Table shows grouping of 
plaque proteins identified in this study separated into the categories of inconsistent/novel 
association with AD, typically down-regulated in AD and typically up-regulated in AD. 
Fisher’s exact test showed that protein groups with significantly higher expression in sAD 
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plaques were predominantly found in previous studies to be up-regulated in AD, whereas 
proteins that had higher expression in rpAD plaques were found to have lower expression in 
AD (p=2.67x10−11).
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Figure 4. Altered levels of plaque-associated astrocytes, but not plaque-associated dystrophic 
neurites in rpAD
The number of plaque-associated astrocytes and dystrophic neurites was identified using 
immunohistochemistry. Quantification of the plaque-associated GFAP burden showed that 
there was significantly less plaque-associated astrocytosis in rpAD (a, b, g; p=0.0199), while 
the number of plaque associated dystrophic neurites was similar in rpAD and sAD (d, e, h). 
(f) The Aβ burden in the cortex was also quantified and showed no significant differences 
between rpAD and sAD. Significance was determined using an unpaired t-test comparing 
the burden of Aβ, plaque-associated astrocytes and plaque-associated dystrophic neurites in 
rpAD (n=18) and sAD (n=14); * p<0.05; data show mean ± SEM. Scale = 50μm
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Table 2
General patient and microdissected plaque characteristics
rpAD sAD
Number of cases 22 (12 Female / 10 Male) 22 (15 Female / 7 Male)
Average age (±SEM) 70.0 (±2.2) years 80.1 (±1.9) years**
Disease duration (±SEM) 9.2 (±1.3) months 122 (±8.0) months***
Post mortem interval 45.1 (±7.7) hours 31.1 (±7.4) hours
Predominant plaque type microdissected 6 neuritic / 5 diffuse / 11 mixed 3 neuritic / 5 diffuse / 14 mixed
Number of plaques microdissected (±SEM) 733 (±52) 751 (±49)
Average size of plaques microdissected (±SEM) 3099 (±213) μm2 2958 (±220) μm2
Average number of proteins identified using LC-MS (±SEM) 941 (±37) 884 (±47)
Data presented as mean ±SEM;
**p<0.01;
***p<0.001
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Table 3
Top 50 most abundant proteins in amyloid plaques
Majority protein name Majority Gene Name Altered in rpAD? Associated 
with AD in 
previous 
proteomic 
studies?
IHC confirmation 
in plaques?
Actin, cytoplasmic 1 ACTB ↑ T P
Glial fibrillary acidic protein GFAP ↓ ↑ ↓ T P Yes - humans[72]
Tubulin alpha-1B chain TUBA1B T Yes – mice[67]
Tubulin beta-4B chain TUBB4B ↑ ↓
Dihydropyrimidinase-related protein 2 DPYSL2 ↑ ↓ Yes – humans 
(using alternative 
name CRMP2)[80]
ATP synthase subunit alpha, mitochondrial ATP5A1 ↑ ↑ ↓ Yes - humans[71]
Pyruvate kinase PKM ↑ ↓
Spectrin alpha chain, non-erythrocytic 1 SPTAN1 ↑ P Yes – humans and 
mice[34]
Creatine kinase B-type CKB ↑ ↓ P
Glyceraldehyde-3-phosphate dehydrogenase GAPDH ↑ ↓
Tubulin beta-2A chain TUBB2A P
Spectrin beta chain, non-erythrocytic 1 SPTBN1 ↑ ↓ P Yes - humans[74]
Syntaxin-binding protein 1 STXBP1 ↑ ↑ ↓
Guanine nucleotide-binding protein G(o) subunit 
alpha
GNAO1 ↓
Heat shock cognate 71 kDa protein HSPA8 ↑
Hemoglobin subunit alpha HBA1 ↑ ↓
Fructose-bisphosphate aldolase A ALDOA ↑ ↓
Amyloid beta A4 protein APP ↓ ↑ P Yes – humans [30]
Hemoglobin subunit beta HBB Yes – mice[15]
ATP synthase subunit beta, mitochondrial ATP5B ↑ ↓ P
Sodium/potassium-transporting ATPase subunit 
alpha-2
ATP1A2 ↓
Alpha-enolase ENO1 ↓ ↑ ↓ T P
Neurofilament light polypeptide NEFL ↑ ↓
Synapsin-1 SYN1 ↓ Yes - mice[32]
Plectin PLEC ↓ ↑
Clathrin heavy chain 1 CLTC ↑ P
14-3-3 protein epsilon YWHAE ↑ ↓ T P
Hexokinase-1 HK1 ↑ ↓ P
Fructose-bisphosphate aldolase C ALDOC ↑ P
Calcium/calmodulin-dependent protein kinase 
type II subunit alpha
CAMK2A ↑ ↓ P Yes - humans[83]
Gamma-enolase ENO2 ↑ ↓ Yes – humans and 
mice[95]
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Majority protein name Majority Gene Name Altered in rpAD? Associated 
with AD in 
previous 
proteomic 
studies?
IHC confirmation 
in plaques?
Dynamin-1 DNM1 ↑ ↑ ↓ T P
Sodium/potassium-transporting ATPase subunit 
alpha-3
ATP1A3 ↓ Yes - in neurites; 
mice[20]
Calmodulin CALM2;CALM1;CALM3 ↑ ↓
Peroxiredoxin -1 PRDX1 ↓ ↑
2,3-cyclic-nucleotide 3-phosphodiesterase CNP ↑
Apolipoprotein E APOE ↑ Yes - humans[84]
Synaptosomal-associated protein 25 SNAP25 ↑ ↑ ↓ P Yes– humans and 
mice[32]
Alpha-internexin INA ↑ P Yes – in neurites; 
humans[21]
Neurofilament medium polypeptide NEFM ↑ ↓ T Yes – in neurites; 
humans[21]
Heat shock protein HSP 90-beta HSP90AB1 ↑ P Yes - humans[38]
Brain acid soluble protein 1 BASP1 ↓
Glutamate dehydrogenase 1, mitochondrial GLUD1 ↑ ↓
Vimentin VIM ↓ ↑ ↓ T P Yes - in surrounding 
astrocytes; 
humans[86]
V-type proton ATPase catalytic subunit A ATP6V1A ↑ ↓
Malate dehydrogenase MDH2 ↑ ↓ T
Myelin basic protein MBP ↑ ↓ Yes - humans[91]
Tenascin-R TNR ↓ P Yes – humans[52]
Ubiquitin UBB ↑ Yes - in neurites; 
humans[59]
Tubulin beta-4A chain TUBB4A ↓
↑: proteins that had higher expression in AD vs control tissue in previous proteomic studies; ↓: proteins that had lower expression in AD vs control 
tissue in previous studies; T: proteins enriched in neurofibrillary tangles; P: proteins enriched in plaques.
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